الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 57 |  |  |
| | | from | 57 | | |
Abstract
COVID-19 infection became an international public health problem due to its rapid spread and high mortality rates. Vaccination against COVID-19 infection was one of the main strategies to combat SARS-CoV-2 and end a devastating pandemic. Several types of vaccines are available in the global market, each with varying levels of immunogenicity and efficacy. Measuring the nAbs levels after immunization is an important standard for evaluating the efficacy of vaccines.
The objectives of this study were to measure the level of SARS-CoV-2 nAbs among Sinopharm vaccine recipients and evaluate the factors for developing these antibodies.
A cross-sectional study was conducted between January 2021 through August 2021 A total of 92 Sinopharm vaccine recipients who had received the vaccine’s second dosage one month earlier were included. Serum samples were collected and tested for nAbs using a commercial ELISA kit.
The findings of the present study were:
1. The median age of participants was 39 years (ranging from 23 to 60 years).
2. The majority of participants were males ( 58.7% ).
3. All participants were working in the medical field. Physicians made up the majority of them (46.7%), followed by technicians (20.7%), workers (12.0%), employees (8.7%), nurses (7.6%), and chemists (4,3%).
4. Among the 92 participants, 17.4% reported a history of SARS-CoV-2 infection prior being vaccinated. They had a higher IH% of nAbs than those who were not previously infected ( 73.63, 45.94, respectively).
5. Among the 92 participants, 52.2% reported absence of any short-term adverse reaction following Sinopharm vaccination, while 6.5% reported the occurrence of fever and 10.9% reported having fatigue, 13.0% reported having headache, 17.4% had pain/swelling at the site of injection, 2.2% of participants had arthralgia/myalgia and 1.0% of participants reported having nausea or vomiting.
6. nAbs were detected in 67.4% of the vaccine recipients and the range of (IH)% was 24.05 to 84.36 %.
7. Hypertensive participants had borderline higher mean titers of nAbs %IH (73.48%).
8. The IH % among smokers was (52.14%) while among non-smokers was (41.22) with no significant differance between both group (p= 0.191).
6.2. Conclusion:
from this study, it can be concluded that:
1. The majority of participants (67.4%) developed nAbs 30 days after the second dose of Sinopharm vaccination.
2. Those who had received the vaccination and previously had SARS-CoV-2 infection reported a higher IH% of nAbs (73.63) than those who were not previously infected (45.94).
3. There was no significant association between nAbs with sociodemographic characteristics (age, sex and occupation) or medical history.
4. Short term adverse reaction such as: pain or swelling at the injection site, headache, fatigue and fever were the most reported reactions among participants after vaccination. None of them was associated with nAbs levels.
6.3. Recommendations
from the results of the present study, the following recommendations are suggested:
1. Encouraging the use of Sinopharm vaccine as a SARS-COV-2 protection means.
2. Further studies are needed for determining the effect of extremes of age (children, and elderly) and other comorbidities on nAbs production following vaccination.